This text is a result of machine translation.
In the half year, the 36billion yuan production expansion plan has been thrown away, and the competition in the stock market of Baijiu is fierce
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Naifei agreed to pay a fine of $59 million to resolve the tax dispute in Italy
Huzhou: there is no time limit for non registered residence residents to continuously pay social security when purchasing houses in central cities